Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the soeiete francaise de greffe de moelle

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 537-546

  Blaise, Didier ^a   Kuentz, Mathieu ^a   Fortanier, Cecile ^a   Bourhis, Jean Henri ^a   Milpied, Noël ^a   Sutton, Laurent ^a   Jouet, Jean Pierre ^a   Attal, Michel ^a   Bordigoni, Pierre ^a   Cahn, Jean Yves ^a   Boiron, Jean Michel ^a   Schuller, Marie Pascale ^a   Moatti, Jean Paul ^a   Michallet, Mauricette ^a  

^a Société Française de Greffe de Moelle et de thé Rapie Cellulaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CYCLOSPORIN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD CELL; CELL TRANSPLANTATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DONOR; ECONOMIC EVALUATION; FEMALE; FRANCE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HOSPITALIZATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIBLING; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

EID: 0033971243     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.537     Document Type: Article

References (48)

1. Gratwohl A, Hermans J, Baldomero H: Blood and marrow transplantation activity in Europe 1995. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 19:407-419, 1997
2. Faucher C, Le Coroller AG, Blaise D, et al: Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: Clinical assessment and cost-effectiveness. Bone Marrow Transplant 14:895-901, 1994
3. Schmitz N, Linch D, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357, 1996
4. Hartmann O, Le Corroller AG, Blaise D, et al: Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs - A randomized, controlled trial. Ann Intern Med 126:600-607, 1997
5. Anderlini P, Korbling M, Dale D, et al: Allogeneic blood stem cell transplantation: Consideration for donors. Blood 90:903-908, 1997
6. Bensinger WI, Weaver CH, Appelbaum F, et al: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor (rhG-CSF). Blood 85: 1655-1658, 1995
7. Körbling M, Prezpiorka D, Huh YO, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 85:1659-1665, 1995
8. Schmitz N, Dreger P, Suttorp M, et al: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666-1672, 1995
9. Blaise D, Jourdan E, Michallet M, et al: Mobilization of healthy donors with lenograstim and transplantation of HLA genoidentical blood progenitors in 54 patients with hematological malignancies: A pilot study. Bone Marrow Transplant 22:1153-1158, 1998
10. Chabannon C, Lafage M, Mozziconacci MJ, et al: Early establishment of chimerism in the B and T lymphoid lineages after transplantation of allogeneic mobilized blood cells in leukemic patients. Transplantation 63:1646-1652, 1997
11. Faucher C, Fortanier C, Le Corroller AG, et al: Clinical, economic and quality of life assessment of lenograstim priming and peripheral blood progenitor cells (PBPC) harvesting for 31 healthy donors. Bone Marrow Transplant 21:840, 1998 (suppl 1, abstr 146)
12. Faucher C, Fortanier C, Viens P, et al: Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation. Bone Marrow Transplant 21:S92-S98, 1998 (suppl 3)
13. Bensinger WI, Clift R, Martin P, et al: Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 88:2794-2800, 1996
14. Thomas E, Storb R, Clift R, et al: Bone marrow transplantation. N Engl J Med 292:832-843;895-902, 1975
15. Blume K, Forman S, O'Donnell M, et al: Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015-1020, 1987
16. Cahn JY, Bordigoni P, Souillet G, et al: The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: A cooperative study of 62 patients. Bone Marrow Transplant 7:1-4, 1991
17. Santos GW, Tutshka PJ, Brookmeyer R, et al: Marrow transplantation for acute nonlymphoblastic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347-1353, 1983
18. Storb R, Deeg HJ, Whitehead J, et al: Methotrexate and cyclosporine compared with cyclosporine alone prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729-735, 1986
19. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients from HL-A-matched sibling donors. Transplantation 18:295-304, 1974
20. Shulman H, Sullivan K, Weiden P, et al: Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204-217, 1980
21. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
22. Eisenberg JM: New drugs and clinical economics: Analysis of cost effectiveness in the assessment of pharmaceutical innovations. Rev Infect Dis 6:S905-S909, 1984 (suppl 4)
23. Le Corroller AG, Moatti JP, Chabannon C, et al: Optimization of peripheral blood stem cell collection by leukapheresis: A case of interaction between economic and clinical assessment of an innovation. J Technol Assess Health Care 15:161-172, 1999
24. Pepe MS, Longton G, Pettinger M, et al: Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: Motivation for and description of new methods. Br J Haematol 83:602-607, 1993
25. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
26. Kaplan E, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
28. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
29. Schmitz N, Bacigalupo A, Hasenclever D, et al: Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:995-1003, 1998
30. Bensinger W, Appelbaum F, Rowley S, et al: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555, 1995
31. Ustun C, Arslan O, Beksac M, et al: A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 5:28-35, 1999
32. Majolino I, Saglio G, Scime R, et al: High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 17:555-560, 1996
33. Urbano-Ispizua A, Garcia-Conde J, Brunet S, et al: High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation: The Spanish Group of Allo PBPCT. Haemalologica 82:683-689, 1997
34. Storek J, Gooley T, Siadak M, et al: Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 90:4705-4709, 1997
35. Glass B, Uharek L, Zeis M, et al: Allogeneic peripheral blood progenitor cell transplantation in a murine model: Evidence for an improved graft-versus-leukemia effect. Blood 90:1694-1700, 1997
36. Pan L, Delmonte J Jr, Jalonen C, et al: Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422-4429, 1995
37. Tayebi H, Tiberghien P, Kuentz M, et al: Comparison of HLA-identical allogeneic bone marrow (BM) versus peripheral blood stem cell (PBSC) transplantation: Phenotypical and functional study of donor T cells in the graft and after hematopoietic reconstitution. Blood 92:140a, 1998 (abstr 562)
38. Buckner C, Clift R, Sanders J, et al: Marrow harvesting from normal donors. Blood 64:630-634, 1984
39. Oziel-Taieb S, Faucher-Barbey C, Chabannon C, et al: Early and fatal immune haemolysis after so-called 'minor' ABO-incompatible peripheral blood stem cell allotransplantalion. Bone Marrow Transplant 19:1155-1156, 1997
40. Lapierre V, Ououzar N, Tramalloni D, et al: Differential immuno-hematological reconstitution after allogeneic peripheral blood versus marrow hematopoietic stem cell transplantation. Blood 92:140a, 1998 (abstr 563)
41. Falzetti F, Aversa F, Minelli O, et al: Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 353:555, 1999 (letter)
42. Viens-Bitker C, Fery-Lemonnier E, Blum-Boisgard C: Cost of allogeneic bone marrow transplantation in four diseases. Health Policy 12:309-317, 1989
43. Barr R, Furlong W, Henwood J, et al: Economic evaluation of allogeneic bone marrow transplantation: A rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 14:1413-1420, 1996
44. Dufoir T, Saux MC, Marit G, et al: Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant 10:323-329, 1992
45. Kay H, Lawler S, Powles R, et al: Cost of bone-marrow transplants in acute myeloid leukaemia. Lancet 17:1067-1069, 1980
46. Griffiths RI, Bass EB, Powe NR, et al: Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant 12:43-48, 1993
47. Finkler SA: The distinction between cost and charge. Ann Intern Med 96:102-109, 1982
48. Drummond MF, Menzin J, Oster G: Methodological issues in economic assessments of new therapies: The case of colony-stimulating factors. Pharmacoeconomics 6:18-26, 1994 (suppl 2)